Skip to content
10-Q

Quarterly Report

ELITE PHARMACEUTICALS INC /NV/ ELTP

0001493152-25-011989

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Aug 14, 2025 1.07B sh
Shares Diluted Q1 2026 · Jun 30, 2025 1.07B sh
Shares Diluted Q1 2026 · Jun 30, 2024 1.08B sh
Capex Q1 2026 · Jun 30, 2025 $218.2K
Capex Q1 2026 · Jun 30, 2024 $778.53K
Operating Cash Flow Q1 2026 · Jun 30, 2025 $14.78M
Operating Cash Flow Q1 2026 · Jun 30, 2024 $3.14M
Stockholders Equity Q1 2026 · Jun 30, 2025 $47.68M
Stockholders Equity Q1 2026 · Mar 31, 2025 $53.52M
Stockholders Equity Q1 2026 · Jun 30, 2024 $58.25M
Stockholders Equity Q1 2026 · Mar 31, 2024 $57.58M
Current Liabilities Q1 2026 · Jun 30, 2025 $10.76M
Current Liabilities Q1 2026 · Mar 31, 2025 $11.84M
Total Liabilities Q1 2026 · Jun 30, 2025 $63.66M
Total Liabilities Q1 2026 · Mar 31, 2025 $42.87M
Current Assets Q1 2026 · Jun 30, 2025 $77.86M
Current Assets Q1 2026 · Mar 31, 2025 $57.74M
Total Assets Q1 2026 · Jun 30, 2025 $111.34M
Total Assets Q1 2026 · Mar 31, 2025 $96.39M
Eps Diluted Q1 2026 · Jun 30, 2025 −$0.01
Eps Diluted Q1 2026 · Jun 30, 2024 $0.00
Eps Basic Q1 2026 · Jun 30, 2025 −$0.01
Eps Basic Q1 2026 · Jun 30, 2024 $0.00
Sga Expense Q1 2026 · Jun 30, 2025 $3.4M
Sga Expense Q1 2026 · Jun 30, 2024 $1.97M
Rd Expense Q1 2026 · Jun 30, 2025 $1.67M
Rd Expense Q1 2026 · Jun 30, 2024 $2.16M
Net Income Q1 2026 · Jun 30, 2025 −$5.88M
Net Income Q1 2026 · Jun 30, 2024 $615.77K
Operating Income Q1 2026 · Jun 30, 2025 $21.7M
Operating Income Q1 2026 · Jun 30, 2024 $3.86M
Gross Profit Q1 2026 · Jun 30, 2025 $27.23M
Gross Profit Q1 2026 · Jun 30, 2024 $8.47M
Cost Of Revenue Q1 2026 · Jun 30, 2025 $12.99M
Cost Of Revenue Q1 2026 · Jun 30, 2024 $10.33M
Revenue Q1 2026 · Jun 30, 2025 $40.21M
Revenue Q1 2026 · Jun 30, 2024 $18.8M